Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
Amanda L McDonell,1 Urpo Kiiskinen,2 Danielle C Zammit,3 Robert W Kotchie,1 Per-Olof Thuresson,3 Claudia Nicolay,4 Thomas Haslam,1 Michiel Bruinsma,5 Anne-Jeanine Janszen-Van Oosterhout,6 Thorsten Otto41IMS Health, London, UK; 2Eli Lilly and Company, Helsinki, Finland; 3IMS Health, Basel, Switzerlan...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-01-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Online Access: | http://www.dovepress.com/estimating-the-real-world-daily-usage-and-cost-for-exenatide-twice-dai-peer-reviewed-article-CEOR |
| _version_ | 1819038279718141952 |
|---|---|
| author | McDonell AL Kiiskinen U Zammit DC Kotchie RW Thuresson PO Nicolay C Haslam T Bruinsma M Janszen-Van Oosterhout AJ Otto T |
| author_facet | McDonell AL Kiiskinen U Zammit DC Kotchie RW Thuresson PO Nicolay C Haslam T Bruinsma M Janszen-Van Oosterhout AJ Otto T |
| author_sort | McDonell AL |
| collection | DOAJ |
| description | Amanda L McDonell,1 Urpo Kiiskinen,2 Danielle C Zammit,3 Robert W Kotchie,1 Per-Olof Thuresson,3 Claudia Nicolay,4 Thomas Haslam,1 Michiel Bruinsma,5 Anne-Jeanine Janszen-Van Oosterhout,6 Thorsten Otto41IMS Health, London, UK; 2Eli Lilly and Company, Helsinki, Finland; 3IMS Health, Basel, Switzerland; 4Eli Lilly and Company, Bad Homburg, Germany; 5IMS Health, Rotterdam, the Netherlands; 6Eli Lilly Nederland, Houten, the NetherlandsBackground: Glucagon-like peptide-1 (GLP-1) receptor agonists are indicated for improvement of glycemic control in adults with type 2 diabetes. Cost is one aspect of treatment to be considered, in addition to clinical benefits, when selecting optimal therapy for a patient. The objective of this study was to estimate the average dose usage and real world daily cost of the GLP-1 receptor agonists, exenatide twice daily and liraglutide once daily, in Germany, the Netherlands, and the UK.Methods: Administrative databases were used to source the data from longitudinal records of dispensed prescriptions. Data were extracted from the IMS Longitudinal Prescription database which captures details of prescriptions dispensed in pharmacies. Information on the dispensed quantity of each product was used to estimate average daily usage per patient. Daily dose usage was multiplied by the public price per unit to estimate daily cost.Results: The dispensed volume in Germany corresponded to a mean dispensed daily dose of 16.81 µg for exenatide twice daily and 1.37 mg for liraglutide (mean daily cost €4.02 and €4.54, respectively). In the Netherlands, average dispensed daily doses of 17.07 µg and 1.49 mg were observed for exenatide twice daily and liraglutide (mean daily cost €3.05 and €3.97, respectively). In the UK, the mean dispensed volume corresponded to a daily usage of 20.49 µg for exenatide twice daily and 1.50 mg for liraglutide (mean daily cost £2.53 and £3.28, respectively).Conclusion: Estimates of average daily dispensed doses of GLP-1 receptor agonists derived from pharmacy data in real world settings corresponded to the dosing recommendation of the summaries of product characteristics. Nevertheless, the mean daily cost of exenatide twice daily was lower than that of liraglutide in Germany, the Netherlands, and the UK. Such estimates can be used to inform health care decision-makers on the real world usage and cost of medications effective in achieving glycemic control in patients with type 2 diabetes.Keywords: type 2 diabetes, exenatide twice daily, liraglutide, dosage, cost, real world |
| first_indexed | 2024-12-21T08:34:47Z |
| format | Article |
| id | doaj.art-129f44d2cfde4b8e9bea84e7e1e2603d |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-12-21T08:34:47Z |
| publishDate | 2015-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-129f44d2cfde4b8e9bea84e7e1e2603d2022-12-21T19:10:05ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812015-01-012015default9510320225Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmaciesMcDonell ALKiiskinen UZammit DCKotchie RWThuresson PONicolay CHaslam TBruinsma MJanszen-Van Oosterhout AJOtto TAmanda L McDonell,1 Urpo Kiiskinen,2 Danielle C Zammit,3 Robert W Kotchie,1 Per-Olof Thuresson,3 Claudia Nicolay,4 Thomas Haslam,1 Michiel Bruinsma,5 Anne-Jeanine Janszen-Van Oosterhout,6 Thorsten Otto41IMS Health, London, UK; 2Eli Lilly and Company, Helsinki, Finland; 3IMS Health, Basel, Switzerland; 4Eli Lilly and Company, Bad Homburg, Germany; 5IMS Health, Rotterdam, the Netherlands; 6Eli Lilly Nederland, Houten, the NetherlandsBackground: Glucagon-like peptide-1 (GLP-1) receptor agonists are indicated for improvement of glycemic control in adults with type 2 diabetes. Cost is one aspect of treatment to be considered, in addition to clinical benefits, when selecting optimal therapy for a patient. The objective of this study was to estimate the average dose usage and real world daily cost of the GLP-1 receptor agonists, exenatide twice daily and liraglutide once daily, in Germany, the Netherlands, and the UK.Methods: Administrative databases were used to source the data from longitudinal records of dispensed prescriptions. Data were extracted from the IMS Longitudinal Prescription database which captures details of prescriptions dispensed in pharmacies. Information on the dispensed quantity of each product was used to estimate average daily usage per patient. Daily dose usage was multiplied by the public price per unit to estimate daily cost.Results: The dispensed volume in Germany corresponded to a mean dispensed daily dose of 16.81 µg for exenatide twice daily and 1.37 mg for liraglutide (mean daily cost €4.02 and €4.54, respectively). In the Netherlands, average dispensed daily doses of 17.07 µg and 1.49 mg were observed for exenatide twice daily and liraglutide (mean daily cost €3.05 and €3.97, respectively). In the UK, the mean dispensed volume corresponded to a daily usage of 20.49 µg for exenatide twice daily and 1.50 mg for liraglutide (mean daily cost £2.53 and £3.28, respectively).Conclusion: Estimates of average daily dispensed doses of GLP-1 receptor agonists derived from pharmacy data in real world settings corresponded to the dosing recommendation of the summaries of product characteristics. Nevertheless, the mean daily cost of exenatide twice daily was lower than that of liraglutide in Germany, the Netherlands, and the UK. Such estimates can be used to inform health care decision-makers on the real world usage and cost of medications effective in achieving glycemic control in patients with type 2 diabetes.Keywords: type 2 diabetes, exenatide twice daily, liraglutide, dosage, cost, real worldhttp://www.dovepress.com/estimating-the-real-world-daily-usage-and-cost-for-exenatide-twice-dai-peer-reviewed-article-CEOR |
| spellingShingle | McDonell AL Kiiskinen U Zammit DC Kotchie RW Thuresson PO Nicolay C Haslam T Bruinsma M Janszen-Van Oosterhout AJ Otto T Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies ClinicoEconomics and Outcomes Research |
| title | Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies |
| title_full | Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies |
| title_fullStr | Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies |
| title_full_unstemmed | Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies |
| title_short | Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies |
| title_sort | estimating the real world daily usage and cost for exenatide twice daily and liraglutide in germany the netherlands and the uk based on volumes dispensed by pharmacies |
| url | http://www.dovepress.com/estimating-the-real-world-daily-usage-and-cost-for-exenatide-twice-dai-peer-reviewed-article-CEOR |
| work_keys_str_mv | AT mcdonellal estimatingtherealworlddailyusageandcostforexenatidetwicedailyandliraglutideingermanythenetherlandsandtheukbasedonvolumesdispensedbypharmacies AT kiiskinenu estimatingtherealworlddailyusageandcostforexenatidetwicedailyandliraglutideingermanythenetherlandsandtheukbasedonvolumesdispensedbypharmacies AT zammitdc estimatingtherealworlddailyusageandcostforexenatidetwicedailyandliraglutideingermanythenetherlandsandtheukbasedonvolumesdispensedbypharmacies AT kotchierw estimatingtherealworlddailyusageandcostforexenatidetwicedailyandliraglutideingermanythenetherlandsandtheukbasedonvolumesdispensedbypharmacies AT thuressonpo estimatingtherealworlddailyusageandcostforexenatidetwicedailyandliraglutideingermanythenetherlandsandtheukbasedonvolumesdispensedbypharmacies AT nicolayc estimatingtherealworlddailyusageandcostforexenatidetwicedailyandliraglutideingermanythenetherlandsandtheukbasedonvolumesdispensedbypharmacies AT haslamt estimatingtherealworlddailyusageandcostforexenatidetwicedailyandliraglutideingermanythenetherlandsandtheukbasedonvolumesdispensedbypharmacies AT bruinsmam estimatingtherealworlddailyusageandcostforexenatidetwicedailyandliraglutideingermanythenetherlandsandtheukbasedonvolumesdispensedbypharmacies AT janszenvanoosterhoutaj estimatingtherealworlddailyusageandcostforexenatidetwicedailyandliraglutideingermanythenetherlandsandtheukbasedonvolumesdispensedbypharmacies AT ottot estimatingtherealworlddailyusageandcostforexenatidetwicedailyandliraglutideingermanythenetherlandsandtheukbasedonvolumesdispensedbypharmacies |